[ad_1]
James Noble, CEO of Adaptimmune Therapeutics PLC (NASDAQ: ADAP), and co-founder, Helen Tayton-Martin, entrust Proactive Investors with the US and UK based cell therapy company to launch its clinical trial SURPASS with its receptor-specific SPEAR (peptide-enhanced affinity receptor) cellular platform, which allows T cells to target and destroy solid tumor cancers.
According to Noble and Tayton-Martin, the SURPASS trial will now begin recruiting up to 30 patients with multiple solid tumor indications in the US, hoping to complete their registration by the end of the year.
Source link
